Xin Yao

951 total citations · 1 hit paper
31 papers, 494 citations indexed

About

Xin Yao is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Xin Yao has authored 31 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 10 papers in Surgery and 10 papers in Molecular Biology. Recurrent topics in Xin Yao's work include Renal cell carcinoma treatment (11 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Xin Yao is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Bladder and Urothelial Cancer Treatments (8 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). Xin Yao collaborates with scholars based in China, Singapore and United States. Xin Yao's co-authors include Hong Luo, Chang-Lu Hu, Xinan Sheng, Jianming Ying, Aiping Zhou, Min-Han Tan, Jiyan Liu, Benkang Shi, Zhisong He and Bin Tean Teh and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Journal of Urology.

In The Last Decade

Xin Yao

27 papers receiving 490 citations

Hit Papers

Open-label, Multicenter, Phase II Study of RC48-ADC, a HE... 2020 2026 2022 2024 2020 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
    2020 192 citations Xinan Sheng, Xieqiao Yan et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xin Yao China 10 203 191 190 164 78 31 494
Linda Cerbone Italy 13 233 1.1× 149 0.8× 167 0.9× 183 1.1× 48 0.6× 34 480
Francesca Barbisan Italy 15 368 1.8× 104 0.5× 209 1.1× 164 1.0× 41 0.5× 36 581
Derui Li China 15 200 1.0× 121 0.6× 162 0.9× 144 0.9× 125 1.6× 43 522
Fernando Rivera Spain 13 372 1.8× 331 1.7× 174 0.9× 157 1.0× 56 0.7× 27 612
Akira Hamada Japan 12 374 1.8× 206 1.1× 79 0.4× 166 1.0× 64 0.8× 63 575
Flavio Mavignier Cárcano Brazil 12 193 1.0× 89 0.5× 109 0.6× 166 1.0× 49 0.6× 34 418
Fabiana Napolitano Italy 12 172 0.8× 220 1.2× 104 0.5× 144 0.9× 37 0.5× 31 448
Òscar Reig Spain 13 303 1.5× 218 1.1× 103 0.5× 190 1.2× 52 0.7× 56 562
Cinzia Baldessari Italy 13 207 1.0× 292 1.5× 107 0.6× 102 0.6× 27 0.3× 43 464

Countries citing papers authored by Xin Yao

Since Specialization
Citations

This map shows the geographic impact of Xin Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xin Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xin Yao more than expected).

Fields of papers citing papers by Xin Yao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xin Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xin Yao. The network helps show where Xin Yao may publish in the future.

Co-authorship network of co-authors of Xin Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Xin Yao. A scholar is included among the top collaborators of Xin Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xin Yao. Xin Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Li, Xiangyu, Peng Lu, Jia Feng, et al.. (2025). MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes. Redox Biology. 84. 103681–103681. 1 indexed citations
5.
Li, Xiaopei, Ben Li, Peng Lü, et al.. (2024). The role of FPR2-mediated ferroptosis in formyl peptide-induced acute lung injury against endothelial barrier damage and protective effect of the mitochondria-derived peptide MOTS-c. International Immunopharmacology. 131. 111911–111911. 6 indexed citations
6.
Wang, Kun, Qing Yang, Guowei Feng, et al.. (2023). Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations. Cancer Medicine. 12(13). 14149–14156. 2 indexed citations
7.
Ye, Dingwei, Xiaojie Bian, Bin Wu, et al.. (2022). Phase II therapeutic equivalence study of Abiraterone Acetate Tablets (I) vs. ZYTIGA® in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 40(16_suppl). e17040–e17040.
8.
Qin, Xiaojian, Dongmei Ji, Weijie Gu, et al.. (2022). Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. BMC Medicine. 20(1). 84–84. 10 indexed citations
9.
Roth, Marc, Paul J. Catalano, Kristen K. Ciombor, et al.. (2021). A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).. Journal of Clinical Oncology. 39(15_suppl). TPS3614–TPS3614. 4 indexed citations
10.
Sheng, Xinan, Dingwei Ye, Aiping Zhou, et al.. (2021). Vorolanib, everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 3, double-blind, multicenter trial.. Journal of Clinical Oncology. 39(15_suppl). 4512–4512. 1 indexed citations
11.
Sheng, Xinan, Xieqiao Yan, Lin Wang, et al.. (2020). Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 27(1). 43–51. 192 indexed citations breakdown →
12.
Qin, Xiaojian, Weiqing Han, Hong Luo, et al.. (2020). SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study.. Journal of Clinical Oncology. 38(6_suppl). 90–90. 1 indexed citations
13.
Tan, Hui Shan, Huihua Li, Chee‐Keong Toh, et al.. (2014). Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. Clinical Genitourinary Cancer. 13(4). e285–e295. 22 indexed citations
14.
Qin, Jianping, et al.. (2014). Retrospective analysis of venograms of hepatic and portal veins: clinical implications for transjugular intrahepatic portosystemic shunt placement.. PubMed. 61(133). 1165–9. 4 indexed citations
15.
Zhou, Xiaoli, et al.. (2014). Elevated expression of CRYAB predicts unfavorable prognosis in non-small cell lung cancer. Medical Oncology. 31(8). 142–142. 26 indexed citations
16.
17.
18.
Li, Qi, et al.. (2013). [Detection and clinical significance of platelet derived growth factor-BB and microvessel density in clear cell renal cell carcinoma].. PubMed. 35(9). 672–7. 1 indexed citations
19.
Yao, Xin, Chao-Nan Qian, Min-Han Tan, et al.. (2007). Two Distinct Types of Blood Vessels in Clear Cell Renal Cell Carcinoma Have Contrasting Prognostic Implications. Clinical Cancer Research. 13(1). 161–169. 76 indexed citations
20.
Yao, Xin, Baocun Sun, Wenlu Li, et al.. (2004). Primary renal malignant fibrous histiocytoma four-case report and review of the literature. Chinese Journal of Clinical Oncology. 1(4). 241–249. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Linda Cerbone Breakdown of academic impact, for papers by Francesca Barbisan Breakdown of academic impact, for papers by Derui Li Breakdown of academic impact, for papers by Fernando Rivera Breakdown of academic impact, for papers by Akira Hamada Breakdown of academic impact, for papers by Flavio Mavignier Cárcano Breakdown of academic impact, for papers by Fabiana Napolitano Breakdown of academic impact, for papers by Òscar Reig Breakdown of academic impact, for papers by Cinzia Baldessari
Rankless by CCL
2026